Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
William J. Sandborn(University of San Diego), Geert D’Haens(Amsterdam University Medical Centers), Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Robert Clare(Pfizer (United States)), Fabio Cataldi(Pfizer (United States)), Anindita Banerjee(Pfizer (United States)), Dong Il Park(Kangbuk Samsung Hospital), Alaa Ahmad(All India Institute of Medical Sciences), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Xavier Hébuterne(Université Côte d'Azur), Satyaprakash Nayak(Pfizer (United States)), Édouard Louis(Centre Hospitalier Universitaire de Liège), Mina Hassan‐Zahraee(Pfizer (United States)), Scott D. Lee(University of Washington), Lisa Brown(Pfizer (United States)), John B. Cheng(Pfizer (United States)), Kenneth J. Gorelick, Jochen Klaus(University Hospital Ulm), Maria Kłopocka(Nicolaus Copernicus University)
Cited by 107
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k